Novartis (NVS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.46
- Estimate
- $2.24
- Surprise
- +9.7%
- Score at report (before → after)
- 5.1 → 5.1/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Novartis (NVS) beat the $2.24 estimate with adjusted EPS of $2.46 — a clear 9.7% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.1/10) to Sell at 5.1/10 after the report.
Coverage in the report window
- Monte Rosa To Receive $37.5M Milestone Payment From Novartis Following Initiation Of Second Phase 2 Trial Of MRT-6160 In — benzinga, 2026-10-28
Where TrendMatrix's rating stands now
TrendMatrix currently rates NVS Sell at 5.2/10.
3 of the last 4 quarters beat the estimate; this quarter's +9.7% surprise compares with a +5.8% four-quarter average.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.3 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Analyst target reached - limited upside remaining
- Leverage penalty (D/E 1.2): -0.5
- Weak growth
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $156.86
- Stop
- $150.96
The stock trades at 29.9× trailing but 16.0× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 74 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 1.8× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-28 — shown for context, not personalized investment advice.
NVS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $298.15B
- P/E (fwd)
- 16.0
- P/E (ttm)
- 29.9
- 52-week range
- $121.57–$170.46
- Off 52-week high
- 8.0%
- RSI (14)
- 74
- Volume vs avg
- 1.81×
- Score today
- 5.2/10